Billiau Alfons, Matthys Patrick
Rega Institute, University of Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium.
Cytokine Growth Factor Rev. 2009 Apr;20(2):97-113. doi: 10.1016/j.cytogfr.2009.02.004. Epub 2009 Mar 5.
This article reviews the main lines of thinking and exploration that have led to our current conception of the role of IFN-gamma in immune defense and autoimmunity. In 1965 the first report appeared describing production of an interferon-like virus inhibitor in cultured human leukocytes following exposure to the mitogen phytohemagglutinin. In the early 1970s the active principle became recognized as being distinct from classical virus-induced interferons, leading to its designation as immune interferon or Type II interferon, and eventually IFN-gamma. Up to that point interest in the factor had come almost exclusively from virologists, in particular those among them who were believers in interferon. Evidence first coming forward in the 1980s that IFN-gamma is indistinguishable from macrophage-activating factor (MAF), then a prototype lymphokine, was the signal for immunologists at large to become interested. Today IFN-gamma ranks among the most important endogenous regulators of immune responses.
本文回顾了一系列主要的思路和探索,正是这些思路和探索使我们形成了目前对γ干扰素在免疫防御和自身免疫中作用的认识。1965年,首篇报告问世,描述了在培养的人白细胞中,经有丝分裂原植物血凝素刺激后产生一种类似干扰素的病毒抑制剂。20世纪70年代初,这种活性物质被确认为不同于经典的病毒诱导干扰素,从而被命名为免疫干扰素或II型干扰素,最终确定为γ干扰素。在此之前,对该因子的研究几乎完全来自病毒学家,尤其是其中那些相信干扰素的人。20世纪80年代首次出现的证据表明,γ干扰素与巨噬细胞活化因子(MAF,当时一种典型的淋巴因子)难以区分,这一发现引起了广大免疫学家的兴趣。如今,γ干扰素是免疫反应最重要的内源性调节因子之一。